コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 s, tuberculosis, chronic herpes simplex, and disseminated histoplasmosis).
2 mab was discontinued in 1 patient because of disseminated histoplasmosis.
3 TNF-alpha therapy are at risk for developing disseminated histoplasmosis.
4 omodulatory therapy may develop pulmonary or disseminated histoplasmosis.
5 h serious infectious complications including disseminated histoplasmosis.
6 patients resulting in two (3.3%) deaths from disseminated histoplasmosis and a herpes virus infection
7 percentage of participants with progressive disseminated histoplasmosis and respiratory symptoms had
8 itis who subsequently developed pulmonary or disseminated histoplasmosis at the Mayo Clinic in Roches
10 osure events and may indicate higher risk of disseminated histoplasmosis, especially in HIV infected
12 uction therapy with L-AmB versus control for disseminated histoplasmosis in AIDS, followed by oral it
13 ned the immunomodulatory effects of IL-12 on disseminated histoplasmosis in immunodeficient SCID mice
14 We report on three patients who developed disseminated histoplasmosis on therapy with TNF-alpha in
15 emic, where delayed diagnosis of progressive disseminated histoplasmosis (PDH) results in high mortal
18 s been previously shown in a murine model of disseminated histoplasmosis that IL-12, IFN-gamma, and T
21 review the published cases of biopsy-proven disseminated histoplasmosis with cholestatic jaundice to